In one paragraphReview in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Augusto ValdiviaMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.ORCID 0000-0002-8039-0007 Pau Mascaro-BaselgaMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Clara Salva-de TorresMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.ORCID 0000-0002-0700-2493 Abraham Geng-CahuaymeRadiotherapy Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.ORCID 0000-0002-5185-5653 Sara TorresanDepartment of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), 33100 Udine, Italy.ORCID 0009-0003-2490-0556 Jesus YaringañoMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.ORCID 0009-0004-4275-1563 Ilaria PrianoMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Patricia IranzoMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.ORCID 0000-0002-9335-2472 Nuria PardoMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Laura MasfarreMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Oriol MirallasMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.ORCID 0000-0002-8492-5195 Karen FarfanMedical Oncology Department, Hospital Nacional Edgardo Rebagliati Martins, Lima 15072, Peru.
Susana CedresMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.ORCID 0000-0002-5068-3124 Pedro RochaMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Alex Martinez-MartiMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Enriqueta FelipMedical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Oligometastatic non-small-cell lung cancer (OMD-NSCLC) has emerged as a biologically and clinically distinct subtype of advanced disease, characterized by limited metastatic burden and a more indolent course. In this narrative review, we examine the current definition of OMD-NSCLC, diagnostic tests, possible biomarkers, and current therapeutic strategies. Biological insights highlight the role of microRNAs in differentiating true oligometastatic state from polymetastatic disease. The main local ablative therapies (LAT) include surgery and radiotherapy. The integration of LAT with systemic therapies has been explored in clinical trials, yielding promising but occasionally inconsistent results. As the therapeutic landscape of OMD-NSCLC patients continues to evolve, refining definitions, identifying predictive biomarkers, and individualizing care are essential steps toward achieving the potential of radical-intent therapy.
Indexed as
biomarkersimmunotherapylocal ablative therapiesnon-small-cell lung canceroligometastasistargeted therapy
Identifiers
PMID40805152
PMCPMC12345762
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390